Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview (Q39094490)

9 September 2017

title

Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview (English)

1 reference

9 September 2017

1 reference

1

Martin J Brodie

0 references

author name string

Martin J Brodie

series ordinal

1

1 reference

9 September 2017

publication date

18 January 2017

1 reference

9 September 2017

1 reference

9 September 2017

volume

31

1 reference

9 September 2017

issue

2

1 reference

9 September 2017

page(s)

135-147

1 reference

Adverse effects of antiepileptic drugs

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Side-effects of antiepileptic drugs: the economic burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Outcomes in newly diagnosed epilepsy in adolescents and adults: Insights across a generation in Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

21 January 2018

Epilepsy: new advances

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Effectiveness of first antiepileptic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Patterns of treatment response in newly diagnosed epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Combining antiepileptic drugs--rational polytherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Antiepileptic drug therapy the story so far

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Current position of phenobarbital in epilepsy and its future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Pharmacological outcomes in newly diagnosed epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Idiosyncratic adverse reactions to antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Enzyme induction with antiepileptic drugs: cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Peripheral retinal dysfunction in patients taking vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Phenobarbital for the treatment of epilepsy in the 21st century: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

The effect of phenobarbitone on cognition in adult patients with new onset epilepsy: a multi-centric prospective study from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A preliminary observation of the adverse effects of phenobarbital among patients with convulsive epilepsy in rural West China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Association of HLA genotypes with phenobarbital hypersensitivity in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Comparative safety of antiepileptic drugs during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Established antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A comparative review of the adverse effects of anticonvulsants in children with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Ethosuximide: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

21 January 2018

Epilepsy in later life

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

The pharmacological treatment of epilepsy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Weight issues for people with epilepsy--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Obesity and endocrine disorders in women taking valproate for epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Valproate in the treatment of epilepsy in girls and women of childbearing potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Interactions between antiepileptic and chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Clinically relevant drug interactions with antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Clonazepam. A review of a new anticonvulsant drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Risk factors for depression in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Benzodiazepines in the treatment of epilepsy. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Clobazam monotherapy for partial-onset or generalized-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Severe persistent visual field constriction associated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Psychiatric adverse events during vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Lamotrigine-associated rash: risk/benefit considerations in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Newer drugs for focal epilepsy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Substance misuse of gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

The effects of adjunctive topiramate on cognitive function in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Topiramate and psychiatric adverse events in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Impact of topiramate on serum bicarbonate concentrations in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Presumed topiramate-induced bilateral acute angle-closure glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Tiagabine-induced stupor in patients with psychogenic nonepileptic seizures: nonconvulsive status epilepticus or encephalopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Hyponatremia from oxcarbazepine and carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Risk Factors of Oxcarbazepine-Induced Hyponatremia in Patients With Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Levetiracetam in refractory epilepsy: a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Levetiracetam monotherapy—Outcomes from an epilepsy clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Psychiatric adverse events during levetiracetam therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Discontinuation of levetiracetam because of behavioral side effects: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Modern management of juvenile myoclonic epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Pregabalin as adjunctive therapy for partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A prospective audit of adjunctive zonisamide in an everyday clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Zonisamide: a review of its use in the management of partial seizures in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Zonisamide and renal calculi in patients with epilepsy: how big an issue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Zonisamide and associated oligohidrosis and hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Adjunctive lacosamide--5 years' clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Pharmacotherapy of epilepsy: newly approved and developmental agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Novel medications for epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Hyponatremia following esclicarbazepine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Prospective audit with adjunctive perampanel: Preliminary observations in focal epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Perampanel for focal epilepsy: insights from early clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

21 January 2018

Drug-resistant epilepsy

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

Factors Influencing the Incidence of Lamotrigine-Related Skin Rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-016-0406-8

21 January 2018

1 reference

12 December 2020

Pharmacodynamic properties of N-dipropylacetic acid

1 reference

12 December 2020

Treatment of Status Epilepticus with a new Benzodiazepine More Active than Diazepam

1 reference

12 December 2020

Antiepileptic drug combinations--have newer agents altered clinical outcomes?

1 reference

12 December 2020

Adjunctive pregabalin for uncontrolled partial-onset seizures: findings from a prospective audit

1 reference

12 December 2020

Topiramate in refractory epilepsy: a prospective observational study

1 reference

12 December 2020

Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group

1 reference

12 December 2020

Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy

1 reference

12 December 2020

Myoclonus associated with the use of gabapentin

1 reference

12 December 2020

Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism

1 reference

12 December 2020

Safety of tiagabine: summary of 53 trials

1 reference

12 December 2020

1 reference

12 December 2020

Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

1 reference

12 December 2020

Severe and disabling constipation: an adverse effect of pregabalin

1 reference

12 December 2020

Teratogenic effects of antiepileptic drugs

1 reference

12 December 2020

Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy

1 reference

12 December 2020

10.1007/S40263-016-0406-8

Identifiers

DOI

1 reference

9 September 2017

1 reference